Third, although patients with severe neurological diseases other than AD were excluded, the inability to accurately ascertain potential comorbidities among participants may introduce uncertainty into the results, particularly concerning plasma NfL as a marker of neuronal damage and cognitive decline. This evidence concerns the gene NEFL and nervous system disorder.